08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AV4025: Phase Ib data

A double-blind, placebo-controlled, Russian Phase Ib trial in 15 treatment-naïve patients with HCV genotype 1b infection showed that once-daily 20 and 40 mg doses of oral AV-4025 for 3 days were well tolerated with no...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

AV4025: Phase Ib started

AllaChem began a double-blind, placebo-controlled, Russian Phase Ib trial to evaluate 20 or 40 mg oral AV4025 once daily for 3 days in about 20 treatment-naïve patients with HCV infection. AllaChem LLC, Hallandale Beach, Fla....
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

AV4025: Phase I data

AllaChem LLC, Hallandale Beach, Fla.   Product: AV4025   Business: Infectious   Molecular target: HCV NS5A protein   Description: HCV NS5A inhibitor   Indication: Treat chronic HCV infection   Endpoint: Safety and pharmacokinetics   Status: Phase I data   Milestone:...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Clinical News

AV4025: Phase I started

Alla Chem LLC, Hallandale Beach, Fla.   Product: AV4025   Business: Infectious   Molecular target: HCV NS5A protein   Description: HCV NS5A inhibitor   Indication: Treat chronic HCV infection   Endpoint: Safety and pharmacokinetics   Status: Phase I started...